Hostname: page-component-5d59c44645-jb2ch Total loading time: 0 Render date: 2024-02-26T01:20:41.160Z Has data issue: false hasContentIssue false

Naldemedine-induced opioid withdrawal with restlessness as the predominant symptom in a palliative care setting

Published online by Cambridge University Press:  23 June 2023

Ryota Sato
Affiliation:
Department of Pharmacy, Maruki Memorial Medical and Social Welfare Center, Saitama, Japan
Mayumi Ishida*
Affiliation:
Department of Psycho-oncology, Saitama Medical University International Medical Center, Saitama, Japan
Nozomu Uchida
Affiliation:
Department of Supportive Oncology and Palliative Medicine, Saitama Medical University International Medical Center, Saitama, Japan Department of General Medicine, Ogano Town Central Hospital, Saitama, Japan
Takehiko Sakimoto
Affiliation:
Department of Palliative Medicine, Asahi General Hospital, Chiba, Japan
Takefumi Yamaguchi
Affiliation:
Department of Palliative Care, Maruki Memorial Medical and Social Welfare Center, Saitama, Japan
Yoshitaka Ooya
Affiliation:
Department of Trauma and Emergency Acute Medicine, Saitama Medical University International Medical Center, Saitama, Japan
Takao Takahashi
Affiliation:
Department of Supportive Oncology and Palliative Medicine, Saitama Medical University International Medical Center, Saitama, Japan
Hideki Onishi
Affiliation:
Department of Psycho-oncology, Saitama Medical University International Medical Center, Saitama, Japan
*
Corresponding author: Mayumi Ishida; Email: mayumi_i@saitama-med.ac.jp

Abstract

Objectives

Opioid analgesics play a central role in cancer pain treatment; however, it has been reported that opioid-induced constipation (OIC) develops in 80% of patients using opioid analgesics and leads to a decrease in quality of life. Naldemedine improves constipation without affecting the analgesic action of opioid analgesics via peripheral μ-opioid receptors.

Methods

We report a terminally ill cancer patient who was diagnosed with opioid withdrawal syndrome (OWS) based on symptoms centered around restlessness and sweating that developed 43 days after administration of naldemedine for OIC.

Results

The patient was a 78-year-old woman who was diagnosed with stage IVB uterine sarcoma in October, 1 year prior to her visit to our clinic,  and underwent chemotherapy after surgery, but the disease became progressive. Thereafter, metastasis to the fourth thoracic vertebrae (Th4) was identified, and loxoprofen and acetaminophen were started for pain at the metastatic site. Oxycodone hydrochloride hydrate 10 mg/day was additionally administered on postoperative day 11, followed by naldemedine 0.2 mg/day for OIC. On the 43rd day after administration, the patient began to wander the hospital ward in a wheelchair and became noticeably restless. OWS due to naldemedine administration was suspected, and naldemedine was discontinued. The symptoms improved 7 days later, and no similar symptoms were observed thereafter.

Significance of results

Patients receiving palliative care often exhibit psychiatric symptoms such as anxiety and depression, but OWS due to naldemedine should also be considered as a potential cause.

Type
Case Report
Copyright
© The Author(s), 2023. Published by Cambridge University Press.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abramowitz, L, Béziaud, N, Labreze, L, et al. (2013) Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: A cross-sectional survey of 520 patients with cancer pain: DYONISOS study. Journal of Medical Economics 16(12), 14231433. doi:10.3111/13696998.2013.851082CrossRefGoogle ScholarPubMed
Brock, C, Olesen, SS, Olesen, AE, et al. (2012) Opioid-induced bowel dysfunction: Pathophysiology and management. Drugs 72(14), 18471865. doi:10.2165/11634970-000000000-00000CrossRefGoogle ScholarPubMed
Coluzzi, F, Scerpa, MS and Pergolizzi, J (2020) Naldemedine: A new option for OIBD. Journal of Pain Research 13, 12091222. doi:10.2147/JPR.S243435CrossRefGoogle ScholarPubMed
Droney, J, Ross, J, Gretton, S, et al. (2008) Constipation in cancer patients on morphine. Supportive Care in Cancer 16(5), 453459. doi:10.1007/s00520-007-0373-1CrossRefGoogle ScholarPubMed
Hjermstad, MJ, Fayers, PM, Haugen, DF, et al. (2011) Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: A systematic literature review. Journal of Pain and Symptom Management 41(6), 10731093. doi:10.1016/j.jpainsymman.2010.08.016CrossRefGoogle ScholarPubMed
Ishida, M, Hiraoka, M, Yaguchi, A, et al. (2021) Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis. Palliative & Supportive Care 20(6), 897899. doi:10.1017/s147895152200044xCrossRefGoogle Scholar
Ishida, M, Uchida, N, Yabuno, A, et al. (2022) Opioid withdrawal syndrome developing after long-term administration of naldemedine. Palliative & Supportive Care 20(3), 445447. doi:10.1017/s1478951521001917CrossRefGoogle ScholarPubMed
Ishii, K, Yamashita, H, Yamaguchi, M, et al. (2020) Naldemedine-induced opioid withdrawal syndrome in a patient with breast cancer without brain metastasis. Internal Medicine 59(2), 293296. doi:10.2169/internalmedicine.3098-19CrossRefGoogle Scholar
Katakami, N, Harada, T, Murata, T, et al. (2017) Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. Journal of Clinical Oncology 35(34), 38593866. doi:10.1200/JCO.2017.73.0853CrossRefGoogle ScholarPubMed
Kawanishi, C, Onishi, H, Kato, D, et al. (2005) Neuroleptic malignant syndrome in cancer treatment. Palliative & Supportive Care 3(1), 5153. doi:10.1017/S147895150505008XCrossRefGoogle ScholarPubMed
Kawanishi, C, Onishi, H, Kato, D, et al. (2007) Unexpectedly high prevalence of akathisia in cancer patients. Palliative & Supportive Care 5(4), 351354. doi:10.1017/S1478951507000545CrossRefGoogle ScholarPubMed
Mesía, R, Virizuela Echaburu, JA, Gómez, J, et al. (2019) Opioid-Induced constipation in oncological patients: New strategies of management. Current Treatment Options in Oncology 20(12). doi:10.1007/s11864-019-0686-6CrossRefGoogle ScholarPubMed
Minagawa, H, Uchitomi, Y, Yamawaki, S, et al. (1996) Psychiatric morbidity in terminally III cancer patients: A prospective study. Cancer 78(5), 11311137. doi:10.1002/(SICI)1097-0142(19960901)78:5<1131::AID-CNCR26>3.0.CO;2-23.0.CO;2-2>CrossRefGoogle ScholarPubMed
Oken, MM, Creech, RH, Tormey, DC, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 5(6), 649655. doi:10.1097/00000421-198212000-00014CrossRefGoogle ScholarPubMed
Osaka, I, Ishiki, H, Yokota, T, et al. (2019) Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: A pooled, subgroup analysis of two randomised controlled studies. ESMO Open 4(4), . doi:10.1136/esmoopen-2019-000527CrossRefGoogle ScholarPubMed
Sato, I, Onishi, H, Kawanishi, C, et al. (2020) Neuroleptic malignant syndrome in patients with cancer: A systematic review. BMJ Supportive & Palliative Care 10(3), 265270. doi:10.1136/bmjspcare-2020-002200CrossRefGoogle ScholarPubMed
Webster, LR, Nalamachu, S, Morlion, B, et al. (2018) Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: A randomized, double-blind, placebo-controlled phase 3 study. Pain 159(5), 987994. doi:10.1097/j.pain.0000000000001174CrossRefGoogle Scholar
Wesson, DR and Ling, W (2003) The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 35(2), 253259. doi:10.1080/02791072.2003.10400007CrossRefGoogle ScholarPubMed